What is the current valuation of the US topical corticosteroids market?

The market valuation was $912.92 Million in 2024. Read More

What is the projected market size for the US topical corticosteroids market by 2035?

The market is projected to reach $1784.18 Million by 2035. Read More

What is the expected CAGR for the US topical corticosteroids market during the forecast period 2025 - 2035?

The expected CAGR is 6.28% during the forecast period. Read More

Which application segment holds the highest valuation in the US topical corticosteroids market?

The Dermatology segment holds the highest valuation, ranging from $400.0 Million to $800.0 Million. Read More

What are the key formulations available in the US topical corticosteroids market?

Key formulations include Creams, Ointments, Lotions, and Gels, with valuations ranging from $162.92 Million to $600.0 Million. Read More

How does the potency of topical corticosteroids affect market segmentation?

The market segments by potency include High Potency, Medium Potency, and Low Potency, with valuations from $182.92 Million to $751.82 Million. Read More

What is the market segmentation based on patient type in the US topical corticosteroids market?

The market segments by patient type include Pediatric, Adult, and Geriatric, with valuations from $109.92 Million to $1060.18 Million. Read More

What trends are influencing the growth of the US topical corticosteroids market?

Trends include increasing demand for dermatological treatments and advancements in formulation technologies. Read More

How does the US topical corticosteroids market compare to other regions?

The US market is characterized by a robust valuation and growth potential, particularly in the Dermatology segment. Read More

US Topical Corticosteroids Market

Q: Who are the key players in the US topical corticosteroids market?

Key players include Pfizer Inc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, and AbbVie Inc. Read More

ID: MRFR/Pharma/15120-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US Topical Corticosteroids Market Research Report By Application (Dermatology, Ophthalmology, Rheumatology, Allergy), By Formulation (Creams, Ointments, Lotions, Gels), By Potency (High Potency, Medium Potency, Low Potency) and By Patient Type (Pediatric, Adult, Geriatric) - Growth & Industry Forecast 2025 To 2035

US Topical Corticosteroids Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.28%

2024 Market Size$ 912.92 Million

2025 Market Size$ 970.25 Million

2035 Market Size$ 1,784.18 Million

Key Players

Pfizer Inc

Bristol-Myers Squibb Company

GlaxoSmithKline plc

Mylan N.V.

Novartis AG

Sanofi S.A.

Trends

Rising Demand for Non-Steroidal Alternatives
Focus on Pediatric Dermatology
Integration of Digital Health Solutions

Opportunities

Rising Healthcare Expenditure
Growing Awareness and Education
Advancements in Formulation Technology

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Application (USD Million)
  1. 4.1.1 Dermatology
  2. 4.1.2 Ophthalmology
  3. 4.1.3 Rheumatology
  4. 4.1.4 Allergy
2. 4.2 Construction, BY Formulation (USD Million)
  1. 4.2.1 Creams
  2. 4.2.2 Ointments
  3. 4.2.3 Lotions
  4. 4.2.4 Gels
3. 4.3 Construction, BY Potency (USD Million)
  1. 4.3.1 High Potency
  2. 4.3.2 Medium Potency
  3. 4.3.3 Low Potency
4. 4.4 Construction, BY Patient Type (USD Million)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adult
  3. 4.4.3 Geriatric
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline plc (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Mylan N.V. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis AG (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi S.A. (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AbbVie Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Hikma Pharmaceuticals PLC (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY FORMULATION
4. 6.4 US MARKET ANALYSIS BY POTENCY
5. 6.5 US MARKET ANALYSIS BY PATIENT TYPE
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY FORMULATION, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY FORMULATION, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY POTENCY, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY POTENCY, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY PATIENT TYPE, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY FORMULATION, 2025-2035 (USD Million)
  3. 7.2.3 BY POTENCY, 2025-2035 (USD Million)
  4. 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Topical Corticosteroids Market Segmentation

US Topical Corticosteroids Market By Application (USD Million, 2025-2035)

Dermatology
Ophthalmology
Rheumatology
Allergy

US Topical Corticosteroids Market By Formulation (USD Million, 2025-2035)

Creams
Ointments
Lotions
Gels

US Topical Corticosteroids Market By Potency (USD Million, 2025-2035)

High Potency
Medium Potency
Low Potency

US Topical Corticosteroids Market By Patient Type (USD Million, 2025-2035)

Pediatric
Adult
Geriatric

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”